Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 9
2020 5
2021 5
2022 6
2023 8
2024 7
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Drug-induced photosensitivity associated with anticancer therapies.
Fattore D, Potestio L, Ortiz Brugués A, Sibaud V. Fattore D, et al. Ital J Dermatol Venerol. 2024 Oct;159(5):555-560. doi: 10.23736/S2784-8671.24.07782-X. Epub 2024 Jun 17. Ital J Dermatol Venerol. 2024. PMID: 38884533 Free article. Review.
Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.
Starace M, Cedirian S, Rapparini L, Pileri A, Carrera C, Giavedoni P, Alonso de Leon MT, Kraehenbuehl L, Elshot YS, Apalla Z, Papegeorgiou C, Nikolaou V, Radevic T, Lengyel Z, Sollena P, Peris K, Rossi E, Fattore D, Koumaki D, Boada A, Forsea AM, Segura S, Freites-Martinez A, Riganti J, Avitan-Hersh E, Saffuri N, Peuvrel L, Dezoteux F, Piraccini BM, Sibaud V. Starace M, et al. Among authors: fattore d. JAMA Dermatol. 2025 Feb 1;161(2):216-218. doi: 10.1001/jamadermatol.2024.5136. JAMA Dermatol. 2025. PMID: 39714856
Autoimmune Skin Diseases and Immune Checkpoint Inhibitors.
Fattore D, Potestio L, Genco L, Pages C, Ortiz A, Fabbrocini G, Sibaud V. Fattore D, et al. Crit Rev Immunol. 2022;42(3):11-22. doi: 10.1615/CritRevImmunol.2023047032. Crit Rev Immunol. 2022. PMID: 37017623 Review.
Oral Minoxidil for Chemotherapy-Induced Alopecia.
Martora F, Vastarella M, Fattore D, Patri A, Fabbrocini G, Cantelli M. Martora F, et al. Among authors: fattore d. Skin Appendage Disord. 2022 Nov;8(6):508-510. doi: 10.1159/000525463. Epub 2022 Jul 6. Skin Appendage Disord. 2022. PMID: 36407639 Free PMC article.
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M, Accorinti M, Romagnuolo M, Marzano A, Di Zenzo G, Moro F, Antiga E, Maglie R, Cozzani E, Parodi A, Gasparini G, Sollena P, De Simone C, Caproni M, Pisano L, Fattore D, Balestri R, Sena P, Vezzoli P, Teoli M, Ardigò M, Vassallo C, Michelerio A, Satta RR, Dika E, Melotti B, Ribero S, Quaglino P. Merli M, et al. Among authors: fattore d. Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37547602 Free PMC article.
The pharmacology of antibiotic therapy in hidradenitis suppurativa.
Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, Fabbrocini G. Marasca C, et al. Among authors: fattore d. Expert Rev Clin Pharmacol. 2020 May;13(5):521-530. doi: 10.1080/17512433.2020.1762571. Epub 2020 Jul 7. Expert Rev Clin Pharmacol. 2020. PMID: 32364806 Review.
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V. Nikolaou VA, et al. Among authors: fattore d. Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. Br J Dermatol. 2022. PMID: 35861701
Successful treatment of eruptive pyogenic granuloma with propranolol.
Fattore D, Di Guida A, Detoraki A, De Fata Salvatores G, Gallo L, Fabbrocini G. Fattore D, et al. Dermatol Ther. 2021 Jul;34(4):e14998. doi: 10.1111/dth.14998. Epub 2021 Jun 18. Dermatol Ther. 2021. PMID: 34028922 Free PMC article. No abstract available.
37 results